|Journal Name||Antioxidants and Redox Signaling|
|Abbreviation||Antioxid Redox Signal|
|Journal Start Year||2001|
|Impact Factor||6.530 (2017)|
|Country||United States (US)|
|Publisher||Mary Ann Liebert Inc|
|Journal Details||Journal Website|
Impact factor :
Antioxidants & Redox Signaling (ARS) is the leading peer-reviewed journal dedicated to understanding the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease. The Journal explores key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics. Cutting-edge research focuses on structural biology, stem cells, regenerative medicine, epigenetics, imaging, clinical outcomes, and preventive and therapeutic nutrition, among other areas.
ARS has expanded to create two unique foci within one journal: ARS Discoveries and ARS Therapeutics. ARS Discoveries (24 issues) publishes the highest-caliber breakthroughs in basic and applied research. ARS Therapeutics(12 issues) is the first publication of its kind that will help enhance the entire field of redox biology by showcasing the potential of redox sciences to change health outcomes.
The abbreviation of the journal is Antioxid Redox Signal. find all journal abbreviation lists from the abbreviation list.
The Journal has been published since 2001.
Mary Ann Liebert Inc is the publisher of the Antioxidants and Redox Signaling. find all journals list from Mary Ann Liebert Inc publisher, click here for a list of journals.
The journal is currently publishing 31 volumes with the help of Mary Ann Liebert Inc publisher.
"Antioxidants and Redox Signaling" journal Print ISSN : 1523-0864, and Online ISSN 1557-7716
The Journal Impact factor is 6.530 (2017).